Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of$ 0.27. This compares to loss of $0.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.70%. A quarter ago, it was expected that this pharmaceutical company would post a loss of$ 0.29 per share when it actually produced a loss of $0.20, delivering a surprise of 31.03%.Over the last four quarters, th ...